Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Lara, Beatriz
Lara, Beatriz
Abstract
Background: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1-2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.
MIDER Authors
Affiliations
Citations
Altmetric:
Date
2022-07
Type
Article
Collections
Citation
Lancet . 2022 Jul 30;400(10349):359-368